Phenotype and Envelope Gene Diversity of Nef-Deleted HIV-1 Isolated from Long-Term Survivors Infected from a Single Source by Gray, Lachlan et al.
 
Phenotype and Envelope Gene Diversity of Nef-Deleted HIV-1
Isolated from Long-Term Survivors Infected from a Single Source
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Gray, Lachlan, Melissa J. Churchill, Jasminka Sterjovski, Kristie
Witlox, Jennifer C. Learmont, John S. Sullivan, Steven L.
Wesselingh, et al. 2007. Phenotype and envelope gene diversity of
nef-deleted HIV-1 isolated from long-term survivors infected from
a single source. Virology Journal 4: 75.
Published Version doi:10.1186/1743-422X-4-75
Accessed February 19, 2015 8:16:15 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4739298
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAABioMed  Central
Page 1 of 12
(page number not for citation purposes)
Virology Journal
Open Access Research
Phenotype and envelope gene diversity of nef-deleted HIV-1 
isolated from long-term survivors infected from a single source
Lachlan Gray1,2, Melissa J Churchill1, Jasminka Sterjovski1,3, Kristie Witlox1,4, 
Jennifer C Learmont5, John S Sullivan5,6, Steven L Wesselingh1,2,3, 
Dana Gabuzda7,8, Anthony L Cunningham9, Dale A McPhee2,10 and 
Paul R Gorry*1,2,3
Address: 1Macfarlane Burnet Institute for Medical Research and Public Health, Victoria, Australia, 2Department of Microbiology and Immunology, 
University of Melbourne, Parkville, Victoria, Australia, 3Department of Medicine, Monash University, Melbourne, Victoria, Australia, 4Department 
of Pathology and Immunology, Monash University, Melbourne, Victoria, Australia, 5Australian Red Cross Blood Service, Sydney, New South 
Wales, Australia, 6Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia, 7Dana-Farber Cancer Institute, Boston, MA, USA, 
8Department of Neurology, Harvard Medical School, Boston, MA, USA, 9Westmead Millennium Institute, Westmead, New South Wales, Australia 
and 10National Serology Reference Laboratory, St. Vincent's Institute for Medical Research, Fitzroy, Victoria, Australia
Email: Lachlan Gray - lachlang@burnet.edu.au; Melissa J Churchill - churchil@burnet.edu.au; Jasminka Sterjovski - jasminka@burnet.edu.au; 
Kristie Witlox - kristiewitlox@hotmail.com; Jennifer C Learmont - JLearmont@arcbs.redcross.org.au; 
John S Sullivan - JSullivan@arcbs.redcross.org.au; Steven L Wesselingh - stevew@burnet.edu.au; 
Dana Gabuzda - dana_gabuzda@dfci.harvard.edu; Anthony L Cunningham - tony_cunningham@wmi.usyd.edu.au; 
Dale A McPhee - dale@nrl.gov.au; Paul R Gorry* - gorry@burnet.edu.au
* Corresponding author    
Abstract
Background: The Sydney blood bank cohort (SBBC) of long-term survivors consists of multiple individuals
infected with attenuated, nef-deleted variants of human immunodeficiency virus type 1 (HIV-1) acquired from a
single source. Long-term prospective studies have demonstrated that the SBBC now comprises slow progressors
(SP) as well as long-term nonprogressors (LTNP). Convergent evolution of nef sequences in SBBC SP and LTNP
indicates the in vivo pathogenicity of HIV-1 in SBBC members is dictated by factors other than nef. To better
understand mechanisms underlying the pathogenicity of nef-deleted HIV-1, we examined the phenotype and env
sequence diversity of sequentially isolated viruses (n = 2) from 3 SBBC members.
Results: The viruses characterized here were isolated from two SP spanning a three or six year period during
progressive HIV-1 infection (subjects D36 and C98, respectively) and from a LTNP spanning a two year period
during asymptomatic, nonprogressive infection (subject C18). Both isolates from D36 were R5X4 phenotype and,
compared to control HIV-1 strains, replicated to low levels in peripheral blood mononuclear cells (PBMC). In
contrast, both isolates from C98 and C18 were CCR5-restricted. Both viruses isolated from C98 replicated to
barely detectable levels in PBMC, whereas both viruses isolated from C18 replicated to low levels, similar to those
isolated from D36. Analysis of env by V1V2 and V3 heteroduplex tracking assay, V1V2 length polymorphisms,
sequencing and phylogenetic analysis showed distinct intra- and inter-patient env evolution.
Conclusion: Independent evolution of env despite convergent evolution of nef may contribute to the in vivo
pathogenicity of nef-deleted HIV-1 in SBBC members, which may not necessarily be associated with changes in
replication capacity or viral coreceptor specificity.
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Background
The Sydney blood bank cohort (SBBC) of long-term survi-
vors (LTS) consists of multiple individuals who became
infected with an attenuated strain of HIV-1 via contami-
nated blood products from a common blood donor
between 1981 and 1984 [1-3]. Viral attenuation has been
attributed to gross deletions in the nef and nef/long-termi-
nal repeat (LTR) overlapping regions of the HIV-1
genome. Despite being infected from a single source,
long-term prospective studies on SBBC members demon-
strated that the cohort now consists of subjects with slow
disease progression (SP), as well as individuals who
remain true long-term nonprogressors (LTNP) and
antiretroviral therapy-naive with stable CD4 counts and
low or undetectable HIV-1 RNA levels [4]. Three SBBC
members (one SP and two LTNP) have since died from
causes unrelated to HIV-1 infection [3,4]. Although the
cohort members had differing clinical courses, a compre-
hensive longitudinal analysis of nef/LTR sequences in the
SBBC donor and four of the transfusion recipients dem-
onstrated a convergent pattern of nef sequence evolution,
characterized by progressive sequence deletions evolving
toward a minimal nef/LTR structure that retains only the
key sequence elements that are required for viral replica-
tion [4]. Thus, HIV-1 pathogenicity in SBBC members is
dictated by viral and/or host determinants other than
those that impose a unidirectional selection pressure on
the nef/LTR region of the HIV-1 genome.
The HIV-1 env gene, which encodes the viral envelope
glycoproteins (Env) is a significant viral determinant in
HIV-1 pathogenesis [reviewed in [5-7]]. HIV-1 Env initi-
ates viral entry via binding to CD4 and subsequently to a
coreceptor, either CCR5 [8-12] or CXCR4 [13]. CCR5-
using (R5) HIV-1 strains predominate at early, asympto-
matic stages of infection. In 40–50% of infected adults,
progression of HIV-1 infection is accompanied by a switch
in coreceptor specificity to HIV-1 variants able to use
CXCR4 or both CCR5 and CXCR4 for entry (X4 or R5X4
strains, respectively) [14,15]. A switch in the specificity of
HIV-1 Env from R5 to X4 or R5X4 is considered an indica-
tor of poor prognosis, partly because it increases the
number of CD4+ cells that are susceptible to cytolytic
infection by HIV-1, and is associated with rapid progres-
sion of HIV-1 infection. R5 HIV-1 variants are present
exclusively in the remaining 50–60% of infected individ-
uals who progress to AIDS, without switching coreceptor
specificity [16,17], and exert pathogenic effects that con-
tribute to HIV-1 progression via mechanisms that remain
poorly understood [5]. Thus, changes in HIV-1 env that
affect viral tropism are important for progression of HIV-
1 infection.
Analysis of inter- and intra-host evolution of env sequence
has provided important insights relevant for HIV-1 trans-
mission and progression. While several reports showed an
inverse relationship between the rate and extent of viral
diversification and progression of HIV-1 infection [18-
25], other studies demonstrated that disease progression
is associated with increasing rates of viral diversity [26-
28]. A later study made significant headway in reconciling
these conflicting studies by identifying 3 distinct phases of
HIV-1 env sequence diversity and divergence during the
asymptomatic period preceding the development of AIDS
[29]; an early phase of variable duration with linear
increases (approximately 1% per year) in both viral diver-
gence and diversity; an intermediate phase characterized
by a continued increase in viral divergence but with a sta-
bilisation or decline in viral diversity; and a late phase
characterized by a stabilisation of viral divergence and a
continued stability or decline in viral diversity. The emer-
gence of X4 HIV-1 variants often coincided with transition
between the early and intermediate phases. More recent
studies identified convergent sequence evolution in env
during the early phase toward a common ancestral
sequence [30], suggesting that HIV-1 recovers certain
ancestral features early in HIV-1 infection that most likely
serve to restore viral fitness. However, other studies exam-
ining HIV-1 progression in individuals harbouring only
R5 variants showed an increase in viral diversity in viral
isolates obtained from patients with AIDS compared to
isolates from asymptomatic individuals [31], raising the
possibility that selection pressures driving HIV-1 evolu-
tion may be distinct in patients who maintain R5 viral var-
iants compared to those who experience a coreceptor
switch.
While the viral determinants underlying the pathogenicity
of nef-deleted HIV-1 strains harbored by SBBC members
are presently unknown, several lines of evidence support
the hypothesis that evolution of HIV-1 env contributes to
disease progression in this cohort; 1) compartmentalized
evolution of HIV-1 V3 env sequence in cerebrospinal fluid
(CSF) of the SBBC donor was shown to contribute to the
development of HIV-associated dementia (HIVD) [32]; 2)
enhanced cell killing in ex vivo human tissue cultures by
HIV-1 isolates from the same SBBC subject was predicted
to result from more efficient coreceptor usage [33]; and 3)
increased Env-mediated fusion was shown to increase the
in vivo pathogenicity of nef-deleted simian immunodefi-
ciency virus (SIV) [34].
To better understand the role of HIV-1 env in the patho-
genesis of nef-deleted HIV-1 strains harbored by SBBC
members, we examined the phenotype and env sequence
diversity of sequential viruses isolated from 3 SBBC mem-
bers. Isolates from the SBBC "donor" (subject D36; SP)
were R5X4 phenotype and replicated to low levels in
peripheral blood mononuclear cells (PBMC). In contrast,
isolates from 2 SBBC "recipients" (subjects C98 and C18;Virology Journal 2007, 4:75 http://www.virologyj.com/content/4/1/75
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SP and LTNP, respectively) were CCR5-restricted with var-
iable replication kinetics. Analysis of env by V1V2 and V3
heteroduplex tracking assay, V1V2 length polymor-
phisms, sequencing and phylogenetic analysis showed
distinct intra- and inter-patient env evolution. Thus, inde-
pendent evolution of env despite convergent evolution of
nef may contribute to the in vivo pathogenicity of nef-
deleted HIV-1 in SBBC members, which may not necessar-
ily be associated with changes in replication capacity or
viral coreceptor specificity.
Results and discussion
Subjects
The clinical history of the study subjects, results of labora-
tory studies and antiretroviral therapies have been
described in detail previously [3,4,32]. The results of lab-
oratory studies relevant for the HIV-1 isolates used in this
study are summarized in Table 1. Briefly, the SBBC donor,
subject D36 presented with HIVD in December 1998 after
being infected with HIV-1 for 18 years without antiretro-
viral therapy. The development of HIVD coincided with a
fall in the CD4 cell count to <200 cells/μl and the presence
of high plasma and CSF HIV-1 RNA levels. The subject was
placed on a highly active antiretroviral therapy (HAART)
regimen of abacavir, nevirapine and zidovidine in January
1999, which suppressed plasma and CSF viral loads to
below detectable levels and resolved the symptoms of
HIVD [32,35]. As reported previously, transfusion recipi-
ent C98 commenced HAART in November 1999 after 16
years of HIV-1 infection, following a steady decline in
CD4+ T-cells and a gradual increase in HIV-1 RNA from
below detectable levels to 1500 RNA copies/ml [3,4]. He
died in March 2002 of amyloidosis, which was not HIV-1
related. Likewise, transfusion recipient C18 died in 1995
of causes unrelated to HIV-1 infection. C18 remained
antiretroviral therapy naive despite 12 years of infection,
with stable CD4 cell counts and low plasma HIV-1 RNA
levels [3]. Thus, subjects D36 and C98 showed evidence of
slow progression while subject C18 remained a long-term
nonprogressor.
HIV-1 isolated from PBMC on 2 consecutive occasions
was used in this study (Table 1). The time between isola-
tions ranged from 2 to 6 years. For the purpose of this
report, the initial isolates are referred to as "early" isolates,
and the subsequent isolates are referred to as "late" iso-
lates (designated "E" and "L", respectively).
Replication kinetics
We first examined the capacity of the HIV-1 isolates to rep-
licate in PHA-activated PBMC (Fig. 1). The R5 ADA and
R5X4 89.6 HIV-1 strains were included as positive con-
trols, and replicated rapidly to high levels peaking at day
7 post-infection (Fig. 1A). Both D36E and D36L viruses
replicated to comparatively low levels, with similar kinet-
ics as ADA and 89.6 (Fig. 1B). Both C18 viruses replicated
with similar kinetics, but peak levels of replication by
C18L were modestly higher (approximately 2-fold) than
those achieved by C18E (Fig. 1D). In contrast, replication
of C98E and C98L viruses was barely detectable (Fig. 1C).
Since D36 and C98 were slow progressors and C18 was a
LTNP, there was no association between replication kinet-
ics of HIV-1 isolates in PBMC and disease progression in
the study subjects. However, the results highlight the het-
erogeneity in replication capacity by nef-deleted HIV-1
strains isolated from multiple subjects infected from a sin-
gle source.
Coreceptor usage
The results of the preceding experiments suggest the exist-
ence of additional phenotypic changes that may contrib-
ute to altered replication capacity in PBMC. We therefore
compared the coreceptor usage of HIV-1 isolates in Cf2-
Luc cells (Fig. 2). The R5 ADA and R5X4 89.6 strains were
included as positive controls and used CCR5 or both
CCR5 and CXCR4 for virus entry, respectively (Fig. 2A), as
expected [9,11,36]. Consistent with results of previous
Table 1: Subjects and laboratory studies
Subject Date of infection Date of blood 
sample
Virus name CD4+ T-cell 
count (cells/μl)a
Viral load 
(RNA copies/ml)b
Antiretroviral drugsc Status of HIV-1 
progressiond
D36 01/1981 07/1995 D36E 552 1500 ABC, AZT, NVP (1/1999–9/2004) SP
01/1999 D36L 160 9900 ABC, NVP, 3TC (9/2004-present)
C18 08/1983 01/1992 C18E 690 N/A None LTNP
03/1994 C18L 809 2805
C98 01/1982 07/1993 C98E 880 N/A d4T, NVP, IND (11/1999-death) SP
11/1999 C98L 585 BD
aCD4+ T-cell levels were measured by flow cytometry.
bPlasma HIV-1 RNA was measured using COBAS AMPLICOR monitor version 1.0 (Roche Molecular Diagnostic Systems, Branchburg, N.J.) prior to 
July 1999 and version 1.5 after July 1999. HIV-1 RNA levels of <400 copies/ml (version 1.0) or <50 copies/ml (version 1.5) were considered below 
detection. BD, below detection; N/A, not available.
cABC, abacavir; AZT, zidovudine; NVP, nevirapine; 3TC, lamivudine; d4T, stavudine; IND, indinavir.
dSP, slow progressor; LTNP, long-term nonprogressor. Comprehensive laboratory data collected since 1993 and detailed clinical history of the 
study subjects has been published previously [3, 4, 32], which was used to classify subjects as SP or LTNP.Virology Journal 2007, 4:75 http://www.virologyj.com/content/4/1/75
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studies [32], D36E and D36L viruses were dual tropic and
used CCR5 and CXCR4 for virus entry (Fig. 2B). C98E,
C98L, C18E and C18L viruses used CCR5 only for virus
entry. Replication of dual tropic D36E and D36L viruses
in PBMC was abolished by preincubation of cells with the
CXCR4 inhibitor AMD3100 [37,38], but was unaffected
by the CCR5 inhibitor TAK-779 [39] (data not shown).
This suggests that the viral quasispecies in D36 isolates are
not a mixture containing R5 variants, and confirms previ-
ous studies that showed infection of PBMC by R5X4
viruses occurs primarily via CXCR4 [40]. Thus, D36 iso-
lates are of R5X4 phenotype, and C18 and C98 isolates are
of R5 phenotype. These results indicate that the presence
of a functional nef gene is not required for HIV-1 to
undergo a switch in coreceptor preference from R5 to
R5X4. However, since D36 harbored R5X4 variants with-
out antiretroviral therapy while remaining asymptomatic
for at least 4 years (Table 1), the results suggest that acqui-
sition of an R5X4 phenotype is not sufficient for rapid dis-
ease progression in the absence of nef. Moreover, the fact
that C98 maintained an R5 virus that replicated poorly in
PBMC, despite evidence of disease progression, suggests
that nef-deleted viruses may acquire increased pathogenic-
ity in vivo by mechanism(s) that are not necessarily associ-
ated with changes in coreceptor usage or enhanced
replicative capacity in vitro.
V1V2 and V3 HTA analysis
Changes in the dominant viral quasispecies may serve to
augment HIV-1 pathogenicity in vivo without increasing
replication capacity or changing coreceptor preference in
vitro  [5]. Therefore, to determine whether distinct viral
Replication kinetics in PBMC Figure 1
Replication kinetics in PBMC. PBMC were infected with equivalent amounts of each virus, as described in the Methods, 
and cultured for 28 days. Virus production in culture supernatants was measured by RT assays. Values shown are means from 
duplicate infections. Error bars represent standard deviations. Results are representative of two independent experiments 
using cells obtained from different donors.Virology Journal 2007, 4:75 http://www.virologyj.com/content/4/1/75
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variants are present in early and late D36, C18 and C98
viruses, Env V1V2 and V3 HTA analyses were conducted.
The V1V2 and V3 HTAs were conducted using [32P]-
labelled probes generated from the R5 ADA Env or the X4
NL4-3 Env (Figs. 3 and 4; left and right panels, respec-
tively). HTA negative controls consisted of reactions con-
taining probe alone or mixed with homologous,
unlabelled target DNA to identify homoduplexes. HTA
positive controls consisted of ADA probe in reactions con-
taining unlabelled NL4-3 or 89.6 Env (Figs. 3 and 4; left
panels), or NL4-3 probe in reactions containing unla-
belled ADA or 89.6 Env (Fig. 3 and 4, right panels) to
identify heteroduplexes. V1V2 HTAs using either probe
demonstrated that C98L contained 2 dominant variants
that were distinct from the single, dominant species found
in C98E (Fig. 3). Similarly, V1V2 HTAs with either probe
demonstrated 2 dominant variants in D36L that were dis-
tinct from 4 variants found in D36E. V1V2 HTAs using the
NL4-3 probe demonstrated 3 variants in C18L that were
distinct from 4 variants found in C18E. However, the ADA
probe appeared to be less sensitive for detecting distinct
V1V2 variants in C18E and C18L viruses. In addition to
the presence of distinct V1V2 heteroduplexes between
Coreceptor usage by primary HIV-1 isolates Figure 2
Coreceptor usage by primary HIV-1 isolates. Cf2-Luc cells were transfected with pcDNA3-CD4 alone or cotransfected 
with pcDNA3-CD4 and pcDNA3 expressing CCR5 or CXCR4 and infected with equivalent amounts of each HIV-1 isolate as 
described in the Methods. Cell lysates were prepared at 48 h post-infection and assayed for luciferase activity. Data are 
expressed as means from duplicate infections. Error bars represent standard deviations. Similar results were obtained in three 
independent experiments.Virology Journal 2007, 4:75 http://www.virologyj.com/content/4/1/75
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viruses isolated from individuals, V1V2 heteroduplexes
were also distinct between subjects.
The V3 heteroduplex patterns also demonstrated distinct
viral variants using either probe (Fig. 4). However, the res-
olution of V3 heteroduplexes was more readily achieved
using the NL4-3 probe. V3 HTAs demonstrated 4 major
variants in C18L that were distinct from a single variant
present in C18E; 2 major variants in C98L that were dis-
tinct from a single major variant present in C98E; and 2
major variants in D36L that were distinct from 2 major
variants present in D36E. Similar to results of the V1V2
HTAs (Fig. 3), the V3 heteroduplexes also appeared to be
distinct between subjects. Together, the results of the
V1V2 and V3 HTAs suggest significant inter- and intra-
patient evolution of HIV-1 Env. In contrast to convergent
sequence evolution previously reported for HIV-1 nef in
the study subjects [4], the V1V2 and V3 HTA results sug-
gest independent evolution of HIV-1 Env.
V1V2 length polymorphism analysis
The V1V2 region of HIV-1 Env contains extensive length
polymorphisms, which can be utilized to compare the
genetic relationships between different viral populations
[41]. Furthermore, V2 region extensions have been associ-
ated with slow progression or long-term nonprogression
of HIV-1 infection [23,42]. We further investigated the
extent of HIV-1 Env diversity in SBBC viral isolates by
measuring V1V2 length polymorphisms using GeneScan
assay (Fig. 5). Although GeneScan analysis is unable to
discriminate between distinct V1V2 variants of the same
length which contain discrete amino acid substitutions, it
has the sensitivity to detect a single nucleotide (nt) dele-
tion or insertion within PCR products [41]. D36E virus
contained 2 dominant V1V2 length polymorphisms
measuring 271 and 277 nt, whereas D36L virus contained
one dominant species measuring 280 nt and 4 minor spe-
cies measuring 255, 268, 269 and 277 nt (Fig. 5). C98E
and C98L viruses each contained single, dominant V1V2
length polymorphisms measuring 241 and 267 nt, respec-
tively. C18E virus contained a single, dominant V1V2
length polymorphism measuring 241 nt, which was iden-
tical in nt length to the dominant species detected in C98E
virus. However, C18L contained 5 distinct V1V2 length
polymorphisms measuring 240, 247, 249, 250 and 252
nt. Thus, in each study subject, late viruses contained var-
iants with V1V2 nt lengths that were distinct from those
detected in early viruses.
These results suggest that significant evolution of V1V2
Env occurred in each of the study subjects, an interpreta-
tion supported also by results of the V1V2 HTA analysis
(Fig. 3). That C18E and C98E viruses contained dominant
variants with identical V1V2 nt length raises the possibil-
ity that these 2 subjects once harboured Env variants with
some shared features. However, the increase in number of
V1V2 length polymorphisms in D36L and C18L viruses
compared to D36E and C18E viruses, respectively, the
shift in dominant V1V2 length polymorphism in C98
viruses, and the lack of overlap between V1V2 length var-
iants detected in D36L, C98L and C18L viruses suggests
divergent evolution of HIV-1 Env in these SBBC study sub-
jects. In contrast to previous studies [23,42], long-term
survival of HIV-1 infection in these subjects was not asso-
ciated with increased V1V2 nt length. Furthermore, signif-
icant increases in V1V2 nt length diversity were observed
in late viruses from a SP (D36) and a LTNP (C18) com-
pared to respective early viruses, and no increase in V1V2
nt length diversity was observed in late virus from a SP
(C98); this suggests that divergent evolution of HIV-1 Env
V3 HTA analysis Figure 4
V3 HTA analysis. The HIV-1 Env V3 region was amplified 
by PCR from genomic DNA of HIV-1 infected PBMC and 
subjected to HTA analysis as described in the Methods. HTA 
analysis using a [32P]-labelled ADA V3 Env probe is shown in 
the left panel, and HTA analysis using a [32P]-labelled NL4-3 
V3 Env probe is shown in the right panel. Similar results were 
obtained in three independent experiments.
V1V2 HTA analysis Figure 3
V1V2 HTA analysis. HIV-1 Env V1V2 regions were ampli-
fied by PCR from genomic DNA of HIV-1 infected PBMC and 
subjected to HTA analysis as described in the Methods. HTA 
analysis using a [32P]-labelled ADA V1V2 Env probe is shown 
in the left panel, and HTA analysis using a [32P]-labelled NL4-
3 V1V2 Env probe is shown in the right panel. Similar results 
were obtained in three independent experiments.Virology Journal 2007, 4:75 http://www.virologyj.com/content/4/1/75
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in the study subjects was neither necessary nor sufficient
for disease progression.
Sequence analysis
The preceding studies showed differences in phenotype
between D36, C98 and C18 viruses and evidence of diver-
gent Env sequence evolution. However, an association
between disease progression and results of phenotypic or
genetic studies could not be made. To determine the
genetic basis underlying differences in viral phenotype,
and to better understand Env sequence changes which
may contribute to HIV-1 progression in SBBC members,
the gp120 region of Env was cloned and the V1 to V3
region of multiple, independent Envs sequenced. Phylo-
genetic analysis of interpatient sequence sets showed
monophyletic clustering of D36 Env sequences (Fig. 6).
The majority of C98 and C18 Env sequences clustered sep-
arately, but 1 C18 Env (C18L.3) clustered with C98 Envs,
suggesting the presence of shared sequence similarities.
This is not unexpected, since C18 and C98 were infected
with a closely related HIV-1 strain and, unlike D36 whose
virus had a coreceptor switch (Fig. 2), both C18 and C98
continued to harbor less evolved R5 variants. Analysis of
intrapatient sequence sets showed that the majority of
C18E and C98E clones cosegregated separately from C18L
and C98L clones, respectively. However, clear cosegrega-
tion of D36E and D36L Envs in the monophyletic D36
cluster was not evident. Since phylogenetic analysis
ignores sequence insertions and deletions, this suggests
that Env sequence evolution in D36 may primarily
involve nucleotide insertions and/or deletions rather than
discrete substitutions.
Multiple sequence alignments of the V1V2 and V3 regions
of Envs cloned from each virus are shown in Fig. 7A and
7B, respectively. The net charge of the V3 regions of D36E
and D36L clones was +6, and the net charge of the V3
regions of C98E, C98L, C18E and C18L clones was +2 or
+3. Consistent with results obtained in coreceptor usage
assays with HIV-1 isolates (Fig. 2), coreceptor usage based
on net V3 charge using the sinsi matrix [43] predicts D36E
and D36L clones to be R5X4 phenotype, and C98E, C98L,
C18E and C18L clones to be R5 phenotype. Although the
presence of a basic residue at position 11 or 25 in V3 is
Phylogenetic analysis Figure 6
Phylogenetic analysis. Env nucleotide sequences were 
subjected to maximum likelihood analysis as described in the 
Methods. Branches labelled in green, blue and red represent 
sequences cloned from subjects C98, C18 and D36, respec-
tively. E, clones from early viruses; L, clones from late 
viruses.
V1V2 length polymorphism analysis Figure 5
V1V2 length polymorphism analysis. The HIV-1 Env 
V1V2 region incorporating a 6-carboxy-fluorescien fluoro-
phore was amplified by PCR from genomic DNA of HIV-1 
infected PBMC and subjected to GeneScan analysis, as 
described in the Methods and elsewhere [41, 56]. (A) GeneS-
can sample files generated from amplified products. (B) Frac-
tion of sequences with a given V1V2 nucleotide length, which 
was calculated from GeneScan sample files. Peaks and bars 
shown in red represent V1V2 amplimers from early viruses, 
and peaks and bars shown in blue represent V1V2 amplimers 
from late viruses. Similar results were obtained in two inde-
pendent experiments.Virology Journal 2007, 4:75 http://www.virologyj.com/content/4/1/75
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strongly associated with CXCR4 usage [44,45], all D36E
and D36L clones lacked basic residues at either position.
Therefore, although D36E and D36L viruses are R5X4
phenotype in transfected Cf2th cells and use CXCR4 for
HIV-1 entry into PBMC (data not shown), CXCR4 use for
HIV-1 entry was not determined by the presence of
charged amino acids at positions 11 or 25. Recently, the
presence of isoleucine at amino acid 326 in V3, or proline
or cysteine residues in V1 was shown to be important for
macrophage (M) tropism of the R5X4 HIV-1 89.6 strain
and other blood-derived, M-tropic R5X4 viruses [46]. In
support of these results, D36E and D36L Envs lack these
genetic changes, and the primary isolates replicate poorly
in cultures of monocyte-derived macrophages (MDM)
compared to 89.6 [47].
The base of the V1V2 stem contains a highly conserved
potential N-linked glycosylation site in the CNTS
sequence of NL4-3 (Fig. 7A), which is present in all but
seven of 208 clade B HIV-1 Env sequences screened from
the Los Alamos National Laboratory HIV Database [48].
One of 3 D36E clones and 2/3 D36L clones lacked a
potential N-linked glycosylation site at this position (Fig.
7A). Similarly, the glycosylation site at this position was
lacking in 1/3 C98E and 1/3 C98L clones. In contrast, the
glycosylation site at the V1V2 stem was conserved among
all C18E and C18L clones, and in contrast to D36 and C98
clones there was a high degree of sequence homology in
this region to that of NL4-3. Elimination of a glycosyla-
tion site at this position is sufficient for CD4-independent
infection by HIV-1 ADA, achieved by altering the position
of the V1V2 loops and exposing the coreceptor binding
site in gp120 [49-52]. Thus, alterations in glycosylation at
the V1V2 stem may serve to enhance receptor binding,
which could contribute to HIV-1 pathogenicity at later
stages of HIV-1 infection. To this end, it is interesting to
note that Env clones lacking this glycosylation site were
present only in SBBC slow progressors (D36 and C98),
whereas the glycosylation site was present in all Envs from
the LTNP (C18). Further sequence analysis of a greater
number of Env clones is required to determine the signif-
icance of this sequence change in SBBC SPs and LTNPs. In
Env V1V2 and V3 amino acid sequences Figure 7
Env V1V2 and V3 amino acid sequences. HIV-1 Env amino acid sequences spanning the V1V2 (A) or V3 (B) regions of Env 
genes cloned into pGEM-T-easy were obtained as described in the Methods. Amino acid alignments are compared to Env from 
HIV-1 NL4-3. Dots indicate residues identical to NL4-3, and dashes indicate gaps.Virology Journal 2007, 4:75 http://www.virologyj.com/content/4/1/75
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addition, further studies to biologically characterize these
Envs are required to determine whether SBBC Envs exhibit
functional changes that could potentially contribute to
HIV-1 pathogenicity.
Conclusion
In this study, we analyzed the phenotype and Env
sequences of HIV-1 present in 3 SBBC members who were
slow progressors or long-term nonprogressors. Early and
late viruses from D36 were R5X4 whereas viruses isolated
from C98 and C18 remained CCR5-restricted, indicating
that a coreceptor switch was neither necessary nor suffi-
cient for disease progression in these subjects. Replication
capacity of these viruses in PBMC ranged from rapid to
barely detectable and was not associated with disease pro-
gression. Although SBBC subjects had evidence of conver-
gent evolution of nef  sequence [4], analysis of Env
diversity by V1V2 and V3 HTA, V1V2 length polymor-
phism assay, and maximum likelihood phylogeny suggest
that Env sequence evolution was divergent in SP and
LTNP subjects. Our results suggest that evolution toward
a pathogenic Env phenotype may occur in long-term sur-
vivors infected with nef-deleted HIV-1, which is not neces-
sarily associated with changes in replication capacity or
coreceptor usage, or degree of Env sequence diversity.
Methods
Isolation of HIV-1
HIV-1 was isolated from patient's PBMC by coculture with
selected PBMC according to published methods [36].
Briefly, 2 × 106 patient PBMC were mixed with 10 × 106
PHA-activated PBMC from 2 normal uninfected donors,
and cocultured for 28 days in RPMI-1640 medium con-
taining 10% (vol/vol) fetal calf serum (FCS) and 20 U/ml
interleukin-2 (IL-2). Fifty percent media changes were per-
formed twice weekly. Five million PHA-activated PBMC
from a different donor were added at every second media
change. Supernatants were tested for reverse transcriptase
(RT) activity using [33P]dTTP incorporation as described
previously [53]. Supernatants testing positive for RT activ-
ity were filtered through 0.45 μm filters and stored at -
80°C.
HIV-1 replication kinetics
Five hundred thousand PHA-activated PBMC were
infected in 48-well tissue culture plates by incubation
with 1 × 106 [33P] cpm RT units of virus supernatant in a
volume of 250 μl for 3 h at 37°C, as described previously
[32,54]. Virus was then removed, and PBMC were washed
3 times with phosphate-buffered saline (PBS) and cul-
tured in RPMI-1640 medium containing 10% (vol/vol)
FCS and 20 U/ml IL-2 for 27 days. Fifty percent medium
changes were performed twice weekly, and supernatants
were tested for HIV-1 replication by RT assays on days 1,
7, 14, 21 and 28 post-infection.
Coreceptor usage
Coreceptor usage by primary HIV-1 isolates was deter-
mined using Cf2-Luc cells expressing CD4 alone, or
expressing CD4 together with CCR5 or CXCR4, as
described previously [32,36,54,55]. Briefly, Cf2-Luc cells
were transfected with 10 μg of plasmid pcDNA3-CD4 and
20 μg of plasmid pcDNA3 containing CCR5 or CXCR4
using the calcium phosphate method, and infected 48 h
later by incubation with 1 × 106 [33P] cpm RT units of HIV-
1 in the presence of 2 μg of Polybrene (Sigma) per ml.
After overnight infection, virus was removed and the cells
were cultured for an additional 48 h prior to lysis in 200
μl of cell lysis buffer (Promega, Madison, Wis.). Cell
lysates were cleared by centrifugation, and assayed for
luciferase activity (Promega) according to the manufac-
turer's protocol.
V1V2 and V3 HTA
The V1V2 probes were generated by PCR amplification of
a 282 bp fragment of the HIV-1 ADA or NL4-3 Env using
primers SK122 (5'-CAAGCCTAAAGCCATGTGTA-3'; cor-
responding to nucleotide positions 6561 to 6580 of NL4-
3) and SK123 (5'-TAATGTATGGGAATTGGCTCAA-3'; cor-
responding to nucleotide positions 6822 to 6843 of NL4-
3). The V3 probes were generated by PCR amplification of
a 239 bp fragment of the HIV-1 ADA or NL4-3 Env using
primers V3c (5'-CCATAATAGTACAGCTGAATG-3'; corre-
sponding to nucleotide positions 7062 to 7081 of NL4-3)
and V3d (5'-ATTTCTGGGTCCCCTCCTGAGGATTG-3';
corresponding to nucleotide positions 7276 to 7301 of
NL4-3). Labelling was achieved by incorporation of α-
[32P]-dCTP in the PCR, which consisted of an initial
denaturation at 95°C for 5 min, followed by 25 cycles of
95°C for 30 sec, 52°C for 1 min, and 72°C for 2 min fol-
lowed by a final extension step of 72°C for 7 min. Unin-
corporated nucleotides were removed using a QIAquick
spin column (Qiagen). The V1V2 and V3 Env target DNA
sequences were generated from genomic DNA of PBMC
infected with each primary HIV-1 isolate by PCR using
primers SK122/SK123 and V3c/V3d, respectively.
Genomic DNA of PBMC infected with HIV-1 ADA, NL4-3
or 89.6 was used as controls. PCR reactions proceeded as
described above, except that radiolabelled dCTP was not
included. Amplimers were purified using a QIAquick spin
column (Qiagen). Heteroduplex reactions were per-
formed as described previously [21] with the following
modifications. The reactions consisted of 1× annealing
buffer [1 M NaCl, 100 mM Tris-HCL (pH 7.5), 20 mM
EDTA], 5 μl unlabelled V1V2 or V3 target PCR product,
and 2.5 μl labelled V1V2 or V3 probe. The reactions were
denatured at 95°C for 4 min and then allowed to anneal
on wet ice for 5 min. The heteroduplexes were separated
in 5.5% (wt/vol) polyacrylamide gels in 1× Tris-borate-
EDTA buffer, and were visualized by autoradiography of
dried HTA gels.Virology Journal 2007, 4:75 http://www.virologyj.com/content/4/1/75
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V1V2 length polymorphism analysis
V1V2 length polymorphisms in HIV-1 Env were quanti-
fied using a fluorescent-based assay that has been
described in detail previously [41]. This technique meas-
ures HIV-1 sequence diversity by taking advantage of fre-
quent length polymorphisms that occur within the V1V2
region of HIV-1 Env, and has the sensitivity to detect a sin-
gle nucleotide deletion or insertion. Briefly, the V1V2
region of HIV-1 Env was amplified from genomic DNA of
PBMC infected with each primary HIV-1 isolate by nested
PCR using outer primers V12-51 and V12-52, and inner
primers V12-50 and V12-53, as described previously [41].
The V12-50 primer used in the second round PCR was
labelled with a fluorophore, 6-carboxy-fluorescien, at the
5' end (PE Biosystems). PCR amplified, fluorescently
labelled products were purified using QIAquick spin col-
umns (Qiagen), separated in 6% (wt/vol) denaturing
polyacrylamide gels using an automated sequencer (ABI
PRISM 377; PE Biosystems) and analysed using GeneScan
software (PE Biosystems). Peaks with areas <10% of the
total peak area were considered not significant, as
described previously [56]. The fraction of sequences in the
viral quasispecies with a given nucleotide length was cal-
culated from GeneScan data and plotted against nucleo-
tide length, as described previously [57].
Env cloning, sequencing and phylogenetic analysis
A 2.1 kb fragment of HIV-1 Env (corresponding to nucleo-
tide positions 6332 to 8452 in NL4-3) was amplified from
genomic DNA of PBMC infected with each primary HIV-1
isolate by nested PCR using outer primers env1A and
env1M [58], and inner primers envKpnI and envBamHI
[59], as described previously [60], and cloned into pGEM-
T Easy (Promega). The V1 to V3 region of 2 to 3 independ-
ent Envs cloned from each primary HIV-1 isolate was
sequenced using a SequiTherm EXCEL II DNA sequencing
kit (Epicenter Technologies, Madison, WI) and a model
4000L LI-COR DNA sequencer (LI-COR, Lincoln, NE).
Nucleotide sequences were aligned using CLUSTALW and
corrected by hand. Phylogeny was estimated by a maxi-
mum likelihood algorithm (DNAml) with a transition/
transversion ratio of 2.0, empirical base frequencies, and
a randomised input order of sequences. Bootstrap values
were calculated from 100 resamplings of the same align-
ment using Seqboot.
Nucleotide sequence accession numbers
The V1 to V3 Env nucleotide sequences reported here have
been assigned GenBank accession numbers DQ665223 to
DQ665240.
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